Kristin C. Schuhwerk
Direttore operativo presso Scorpion Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Adam Friedman | M | - |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | 4 anni |
Keith Flaherty | M | 53 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Jean-Francois Formela | M | 67 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Shelley Chu | M | 54 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Timothy Haines | M | 67 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Otello Stampacchia | M | 55 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | 4 anni |
Oleg Nodelman | M | 47 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Saurabh Saha | M | 47 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | 2 anni |
Arjun Goyal | M | - |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Joanne M. Protano | F | 55 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 8 anni |
James Manuso | M | 75 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 anni |
Stephen Hill | M | 65 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 anni |
Axel Hoos | M | 54 |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | 3 anni |
George R. Vaughn | M | 70 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | - |
Christopher J. Pazoles | M | 73 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 9 anni |
M. Taylor Burtis | F | 72 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Simyon S. Palmin | M | 79 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 12 anni |
Michael J. Doyle | M | 65 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 6 anni |
Kimberly A. Hawkins | F | 51 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 anni |
Guy Padbury | M | - |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 20 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Kristin C. Schuhwerk
- Contatti personali